Actively Recruiting
Outcome of 68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Primary Aldosteronism
Led by Qifu Li · Updated on 2024-04-30
320
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
Sponsors
Q
Qifu Li
Lead Sponsor
T
The Affiliated Hospital Of Southwest Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
To compare the 68Ga-Pentixafor PET/CT and adrenal vein sampling on the long-term outcomes of primary aldosteronism (PA) patients with adrenal nodule (≥1cm)
CONDITIONS
Official Title
Outcome of 68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Primary Aldosteronism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide written informed consent
- Have an aldosterone-renin ratio (ARR) ≥ 20 (pg/ml)/(µIU/ml) or ARR ≥ 30 (ng/dL)/(ng/ml/hr) plus at least one positive confirmatory test for primary aldosteronism
- Be willing to undergo surgery
- Have hypertension and be aged between 18 and 70 years
- Have an adrenal gland nodule measuring 1 cm or larger on CT or MRI scan
You will not qualify if you...
- Have autonomous cortisol secretion with cortisol after 1 mg dexamethasone suppression test ≥ 50 nmol/l
- Meet bypass adrenal vein sampling criteria: younger than 35 years, spontaneous low potassium, unilateral adrenal low-density adenoma ≥ 1 cm, or plasma aldosterone > 300 pg/ml
- Suspected familial hyperaldosteronism or Liddle syndrome (age < 20 years, hypertension and low potassium, or family history)
- Suspected pheochromocytoma or adrenal carcinoma
- Have an active malignant tumor
- Have a history of adrenalectomy or adrenal insufficiency
- Use long-term glucocorticoids
- Are pregnant or lactating, or have alcohol/drug abuse or mental disorders
- Have congestive heart failure NYHA class III or IV
- Have serious cardiovascular or cerebrovascular disease in past 3 months
- Have severe anemia (hemoglobin < 60 g/L)
- Have serious liver dysfunction or chronic kidney disease (AST or ALT > 3 times upper limit, or eGFR < 30 ml/min/1.73 m2)
- Have systemic inflammatory response syndrome (SIRS)
- Have uncontrolled diabetes (fasting blood glucose ≥ 13.3 mmol/L)
- Are obese (BMI ≥ 35 kg/m²) or underweight (BMI ≤ 18 kg/m²)
- Have untreated aneurysm
- Have other comorbidities that might interfere with treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affilated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016
Actively Recruiting
Research Team
Q
Qifu Li, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here